Miller Miles A, Arlauckas Sean, Weissleder Ralph
Center for Systems Biology, Massachusetts General Hospital, USA.
Department of Radiology, Massachusetts General Hospital, USA.
Nanotheranostics. 2017 Jul 6;1(3):296-312. doi: 10.7150/ntno.20564. eCollection 2017.
Anticancer nanotherapeutics have shown mixed results in clinical trials, raising the questions of whether imaging should be used to i) identify patients with a higher likelihood of nanoparticle accumulation, ii) assess nanotherapeutic efficacy before traditional measures show response, and iii) guide adjuvant treatments to enhance therapeutic nanoparticle (TNP) delivery. Here we review the use of a clinically approved MRI nanoparticle (ferumoxytol, FMX) to predict TNP delivery and efficacy. It is becoming increasingly apparent that nanoparticles used for imaging, despite clearly distinct physicochemical properties, often co-localize with TNP in tumors. This evidence offers the possibility of using FMX as a generic "companion diagnostic" nanoparticle for multiple TNP formulations, thus potentially allowing many of the complex regulatory and cost challenges of other approaches to be avoided.
抗癌纳米疗法在临床试验中的结果参差不齐，这引发了一些问题，即是否应利用成像技术来：i）识别纳米颗粒蓄积可能性更高的患者；ii）在传统指标显示出反应之前评估纳米疗法的疗效；iii）指导辅助治疗以增强治疗性纳米颗粒（TNP）的递送。在此，我们综述了一种临床批准的MRI纳米颗粒（多聚麦芽糖铁，FMX）在预测TNP递送和疗效方面的应用。越来越明显的是，用于成像的纳米颗粒尽管具有明显不同的物理化学性质，但在肿瘤中常常与TNP共定位。这一证据为将FMX用作多种TNP制剂的通用“伴随诊断”纳米颗粒提供了可能性，从而有可能避免其他方法所面临的许多复杂的监管和成本挑战。
